Literature DB >> 25661408

Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death.

Rajal K Mody1, Weidong Gu1, Patricia M Griffin1, Timothy F Jones2, Josh Rounds3, Beletshachew Shiferaw4, Melissa Tobin-D'Angelo5, Glenda Smith6, Nancy Spina6, Sharon Hurd7, Sarah Lathrop8, Amanda Palmer9, Effie Boothe2, Ruth E Luna-Gierke1, Robert M Hoekstra1.   

Abstract

OBJECTIVE: To assess the clinical spectrum of postdiarrheal hemolytic uremic syndrome (D(+)HUS) hospitalizations and sought predictors of in-hospital death to help identify children at risk of poor outcomes. STUDY
DESIGN: We assessed clinical variables collected through population-based surveillance of D(+)HUS in children <18 years old hospitalized in 10 states during 1997-2012 as predictors of in-hospital death by using tree modeling.
RESULTS: We identified 770 cases. Of children with information available, 56.5% (430 of 761) required dialysis, 92.6% (698 of 754) required a transfusion, and 2.9% (22 of 770) died; few had a persistent dialysis requirement (52 [7.3%] of 716) at discharge. The tree model partitioned children into 5 groups on the basis of 3 predictors (highest leukocyte count and lowest hematocrit value during the 7 days before to 3 days after the diagnosis of hemolytic uremic syndrome, and presence of respiratory tract infection [RTI] within 3 weeks before diagnosis). Patients with greater leukocyte or hematocrit values or a recent RTI had a greater probability of in-hospital death. The largest group identified (n = 533) had none of these factors and had the lowest odds of death. Many children with RTI had recent antibiotic treatment for nondiarrheal indications.
CONCLUSION: Most children with D(+)HUS have good hospitalization outcomes. Our findings support previous reports of increased leukocyte count and hematocrit as predictors of death. Recent RTI could be an additional predictor, or a marker of other factors such as antibiotic exposure, that may warrant further study. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25661408     DOI: 10.1016/j.jpeds.2014.12.064

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens.

Authors:  Gillian A M Tarr; Linda Chui; Bonita E Lee; Xiao-Li Pang; Samina Ali; Alberto Nettel-Aguirre; Otto G Vanderkooi; Byron M Berenger; James Dickinson; Phillip I Tarr; Steven Drews; Judy MacDonald; Kelly Kim; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

Review 2.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

3.  A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network.

Authors:  Gianluigi Ardissino; Francesca Tel; Sara Testa; Fabio Paglialonga; Selena Longhi; Laura Martelli; Silvia Consolo; Damiano Picicco; Antonella Dodaro; Laura Daprai; Rosaria Colombo; Milena Arghittu; Michela Perrone; Giovanna Chidini; Stefano Scalia Catenacci; Isabella Cropanese; Dario Consonni
Journal:  Eur J Pediatr       Date:  2018-08-10       Impact factor: 3.183

4.  Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.

Authors:  Ryan S McKee; David Schnadower; Phillip I Tarr; Jianling Xie; Yaron Finkelstein; Neil Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Annie Rominger; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Darcy Beer; Martin Bitzan; Christopher M Pruitt; Kenneth Yen; Garth D Meckler; Amy C Plint; Stuart Bradin; Thomas J Abramo; Serge Gouin; April J Kam; Abigail Schuh; Fran Balamuth; Tracy E Hunley; John T Kanegaye; Nicholas E Jones; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

5.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

6.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

7.  Case 6: An Infant Presenting with Hematuria and Pallor.

Authors:  Lauren C Riney; Jennifer D Treasure; Charles D Varnell; Holly Depinet
Journal:  Pediatr Rev       Date:  2018-02

8.  Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity.

Authors:  Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr
Journal:  Int J Med Microbiol       Date:  2018-10-10       Impact factor: 3.473

Review 9.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

10.  Enterohemorrhagic colitis with disseminated intravascular coagulation.

Authors:  Gregory Taroyan; Andrew L Juergens
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.